Changes in Serum Cytokines May Predict Therapeutic Efficacy of Tofacitinib in Rheumatoid Arthritis
Objective. Tofacitinib is a novel therapy for rheumatoid arthritis (RA). The aim of this study was to measure various serum cytokines levels and to explore potential markers predictive of therapeutic efficacy of tofacitinib for RA patients. Methods. Thirty-two patients with RA were given tofacitinib...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2019/5617431 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832564767856787456 |
|---|---|
| author | Yuxuan Li Lin Yuan Jie Yang Yue Lei Hui Zhang Liping Xia Hui Shen Jing Lu |
| author_facet | Yuxuan Li Lin Yuan Jie Yang Yue Lei Hui Zhang Liping Xia Hui Shen Jing Lu |
| author_sort | Yuxuan Li |
| collection | DOAJ |
| description | Objective. Tofacitinib is a novel therapy for rheumatoid arthritis (RA). The aim of this study was to measure various serum cytokines levels and to explore potential markers predictive of therapeutic efficacy of tofacitinib for RA patients. Methods. Thirty-two patients with RA were given tofacitinib (5 mg bid). Serum cytokines levels of Th1 (IFN-γ), Th2 (IL-6), Th17 (IL-17), Tregs (IL-35), and TNF-α were detected by enzyme-linked immunosorbent assays. Results. Disease activity was significantly decreased as early as week 4 after tofacitinib treatment. Serum IL-35 levels were significantly increased and serum levels of TNF-α, IL-17, IL-6, and IFN-γ were significantly reduced in response to tofacitinib since week 4. Conclusions. After treatment with tofacitinib, RA patients may benefit from monitoring of disease activity as early as week 4. IL-35 also might be a predictive indicator of the disease activity and drug efficacy. Meanwhile, tofacitinib might be CS-sparing in RA. |
| format | Article |
| id | doaj-art-9797b2ef6a3c4eb6acb7198995c527b5 |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-9797b2ef6a3c4eb6acb7198995c527b52025-02-03T01:10:13ZengWileyMediators of Inflammation0962-93511466-18612019-01-01201910.1155/2019/56174315617431Changes in Serum Cytokines May Predict Therapeutic Efficacy of Tofacitinib in Rheumatoid ArthritisYuxuan Li0Lin Yuan1Jie Yang2Yue Lei3Hui Zhang4Liping Xia5Hui Shen6Jing Lu7Department of Rheumatology and Immunology, The First Affiliated Hospital of China Medical University, 155 Nanjing North Street, Shenyang, Heping District 110001, ChinaDepartment of Rheumatology and Immunology, The First Affiliated Hospital of China Medical University, 155 Nanjing North Street, Shenyang, Heping District 110001, ChinaDepartment of Rheumatology and Immunology, The First Affiliated Hospital of China Medical University, 155 Nanjing North Street, Shenyang, Heping District 110001, ChinaDepartment of Rheumatology and Immunology, The First Affiliated Hospital of China Medical University, 155 Nanjing North Street, Shenyang, Heping District 110001, ChinaDepartment of Rheumatology and Immunology, The First Affiliated Hospital of China Medical University, 155 Nanjing North Street, Shenyang, Heping District 110001, ChinaDepartment of Rheumatology and Immunology, The First Affiliated Hospital of China Medical University, 155 Nanjing North Street, Shenyang, Heping District 110001, ChinaDepartment of Rheumatology and Immunology, The First Affiliated Hospital of China Medical University, 155 Nanjing North Street, Shenyang, Heping District 110001, ChinaDepartment of Rheumatology and Immunology, The First Affiliated Hospital of China Medical University, 155 Nanjing North Street, Shenyang, Heping District 110001, ChinaObjective. Tofacitinib is a novel therapy for rheumatoid arthritis (RA). The aim of this study was to measure various serum cytokines levels and to explore potential markers predictive of therapeutic efficacy of tofacitinib for RA patients. Methods. Thirty-two patients with RA were given tofacitinib (5 mg bid). Serum cytokines levels of Th1 (IFN-γ), Th2 (IL-6), Th17 (IL-17), Tregs (IL-35), and TNF-α were detected by enzyme-linked immunosorbent assays. Results. Disease activity was significantly decreased as early as week 4 after tofacitinib treatment. Serum IL-35 levels were significantly increased and serum levels of TNF-α, IL-17, IL-6, and IFN-γ were significantly reduced in response to tofacitinib since week 4. Conclusions. After treatment with tofacitinib, RA patients may benefit from monitoring of disease activity as early as week 4. IL-35 also might be a predictive indicator of the disease activity and drug efficacy. Meanwhile, tofacitinib might be CS-sparing in RA.http://dx.doi.org/10.1155/2019/5617431 |
| spellingShingle | Yuxuan Li Lin Yuan Jie Yang Yue Lei Hui Zhang Liping Xia Hui Shen Jing Lu Changes in Serum Cytokines May Predict Therapeutic Efficacy of Tofacitinib in Rheumatoid Arthritis Mediators of Inflammation |
| title | Changes in Serum Cytokines May Predict Therapeutic Efficacy of Tofacitinib in Rheumatoid Arthritis |
| title_full | Changes in Serum Cytokines May Predict Therapeutic Efficacy of Tofacitinib in Rheumatoid Arthritis |
| title_fullStr | Changes in Serum Cytokines May Predict Therapeutic Efficacy of Tofacitinib in Rheumatoid Arthritis |
| title_full_unstemmed | Changes in Serum Cytokines May Predict Therapeutic Efficacy of Tofacitinib in Rheumatoid Arthritis |
| title_short | Changes in Serum Cytokines May Predict Therapeutic Efficacy of Tofacitinib in Rheumatoid Arthritis |
| title_sort | changes in serum cytokines may predict therapeutic efficacy of tofacitinib in rheumatoid arthritis |
| url | http://dx.doi.org/10.1155/2019/5617431 |
| work_keys_str_mv | AT yuxuanli changesinserumcytokinesmaypredicttherapeuticefficacyoftofacitinibinrheumatoidarthritis AT linyuan changesinserumcytokinesmaypredicttherapeuticefficacyoftofacitinibinrheumatoidarthritis AT jieyang changesinserumcytokinesmaypredicttherapeuticefficacyoftofacitinibinrheumatoidarthritis AT yuelei changesinserumcytokinesmaypredicttherapeuticefficacyoftofacitinibinrheumatoidarthritis AT huizhang changesinserumcytokinesmaypredicttherapeuticefficacyoftofacitinibinrheumatoidarthritis AT lipingxia changesinserumcytokinesmaypredicttherapeuticefficacyoftofacitinibinrheumatoidarthritis AT huishen changesinserumcytokinesmaypredicttherapeuticefficacyoftofacitinibinrheumatoidarthritis AT jinglu changesinserumcytokinesmaypredicttherapeuticefficacyoftofacitinibinrheumatoidarthritis |